Summary of West's Q3 2025 Earnings Call

1Key Financial Results and Metrics:

Revenues: $805 million, up 5% organically, exceeding expectations.

Adjusted Operating Margin: 21.1%, slightly down 40 basis points year-over-year but ahead of guidance.

Adjusted EPS: $1.96, a 6% increase compared to the prior year and $0.26 above guidance.

Gross Margin: 36.6%, up 120 basis points year-over-year, driven by a favorable product mix and operational efficiencies.

Free Cash Flow: $294 million, a 54% increase year-over-year, attributed to a 23% reduction in capital expenditures.

2Strategic Updates and Business Highlights:

Proprietary Products Segment: Revenues of $648 million, up 5.1% organically, with strong growth in HVP components (up 13% organically), particularly from GLP-1 elastomers, which now account for 9% of total sales.

Contract Manufacturing Segment: Revenues of $157 million, growing 4.9% organically, driven by self-injected devices for obesity and diabetes.

Leadership Changes: New CFO Bob McMahon and CTO Davis Matter appointed, expected to enhance innovation and operational efficiency.

Ongoing Projects: 375 Annex 1 upgrade projects in progress, anticipated to contribute 200 basis points of growth this year.

3Forward Guidance and Outlook:

Full-Year Revenue Guidance: Increased to $3.06 billion to $3.07 billion, representing reported growth of 5.8% to 6.1%.

Adjusted EPS Guidance: Raised to $7.06 to $7.11, reflecting year-on-year growth of 4.6% to 5.3%.

Q4 Revenue Guidance: Expected between $790 million to $800 million, with organic growth impacted by a prior year incentive fee.

2026 Outlook: Anticipated continuation of growth in HVP components driven by GLP-1s and Annex 1 upgrades, though some caution due to potential contract transitions.

4Bad News, Challenges, or Points of Concern:

HVP Delivery Device Business: Revenues declined year-over-year due to a $19 million incentive payment received last year, with ongoing evaluations for maximizing business value.

Contract Manufacturing Transition: The exit from the CGM contract by mid-2026 poses a $40 million headwind, though management is optimistic about backfilling with higher-margin business.

Market Dynamics: While demand is improving, there are still uncertainties regarding new drug approvals and potential headwinds from regulatory changes affecting customer investment decisions.

5Notable Q&A Insights:

Long-Term Growth: Management expressed confidence in achieving long-term growth targets (7%-9%) driven by HVP components, particularly in biologics and GLP-1s.

Sustainability of GLP-1 Growth: While GLP-1 elastomer growth has been strong, management indicated that growth rates may normalize as the market matures.

Visibility and Risk Management: The company is focused on improving visibility into market dynamics and reducing risks, with ongoing discussions with customers to ensure alignment with their needs.

Capital Allocation: Plans to define a clearer capital allocation strategy, balancing between share repurchases and potential M&A opportunities. This summary encapsulates the key points from West's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, guidance, and areas of concern.